BioCryst Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioCryst Pharmaceuticals, Inc. (BCRX) on January 8, 2025. The report discloses a material change regarding the pricing of the Company's product, ORLADEYO® (berotralstat), effective as of the filing date.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The only specific financial data point disclosed is the change in the Wholesale Acquisition Cost (WAC) for ORLADEYO®:
- Previous WAC: $42,366.03 per 28-day pack (150mg or 110mg capsules).
- New WAC: $44,484.33 per 28-day pack (150mg or 110mg capsules).
- Effective Date: January 8, 2025.
Material Changes
The primary material change is the implementation of a price increase for ORLADEYO® in the United States. The WAC has increased by $2,118.30 per 28-day pack, representing an approximate 5.0% increase over the prior cost.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard disclaimer that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the impact of the 5.0% WAC increase on future revenue projections and gross margins.
- Confirm whether the price increase is expected to affect patient access or insurance reimbursement rates.
- Review subsequent quarterly filings (10-Q/10-K) to assess the realized financial impact of this pricing change.
- Check for any concurrent regulatory or payer responses to the price adjustment.